Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo drug CagriSema shows promise for major weight loss in 3-Year trial

NCT ID NCT06780449

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called CagriSema (a mix of two drugs) for helping people with obesity lose weight. About 400 adults with a BMI of 35 or higher will receive either CagriSema or a placebo for 2 years, then some will continue or slowly stop the medicine for another year. The goal is to see how much weight they lose and if the medicine is safe over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Male or female. * Age above or equal to 18 years at the time of signing informed consent. * Body mass index (BMI) greater than or equal to (\>=) 35.0 kilograms per meter square (kg/m\^2). Exclusion criteria: * Glycated haemoglobin (HbA1c) \>= 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • APDP - Associação Protectora dos Diabéticos de Portugal

    Lisbon, 1250-189, Portugal

  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus

    Aarhus, 8200, Denmark

  • Addenbrooke's Hospital_Cambridge

    Cambridge, CB2 0QQ, United Kingdom

  • Aintree University Hospital

    Liverpool, L9 7AL, United Kingdom

  • Alpha Recherche Clinique - Lebourgneuf

    Québec, G2J 0C4, Canada

  • CHU Helora - Hôpital de Mons - Site Constantinople

    Mons, 7000, Belgium

  • CUF Descobertas

    Lisbon, 1998-018, Portugal

  • Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie

    Brussels, 1200, Belgium

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Dr. M.B. Jones Inc

    Victoria, British Columbia, V8V 4A1, Canada

  • East West Medical Research Institute_Honolulu

    Honolulu, Hawaii, 96814, United States

  • Gentofte Hospital - Center for Klinisk Metabolisk Forskning

    Hellerup, 2900, Denmark

  • Holston Medical Group_Bristol

    Bristol, Tennessee, 37620, United States

  • Hospital Cuf Descobertas S.A.

    Lisbon, 1998-018, Portugal

  • Hospital Luz Arrabida, S.A.

    Vila Nova de Gaia, 4400-346, Portugal

  • Hvidovre Hospital Endokrinologisk forsknings afsnit 159

    Hvidovre, 2650, Denmark

  • Joint Clinical Research Facility - Swansea

    Swansea, SA2 8PP, United Kingdom

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Musgrove Park Hospital

    Taunton, TA1 5DA, United Kingdom

  • North Texas Endocrine Center

    Dallas, Texas, 75231, United States

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, L8L 5G4, Canada

  • Royal London Hospital - Blizard Institute

    London, E1 2AJ, United Kingdom

  • Sjællands Universitetshospital, Køge - Medicinsk Afdeling

    Køge, 4600, Denmark

  • Southmead Hospital

    Bristol, BS10 5NB, United Kingdom

  • Spartanburg Medical Research

    Spartanburg, South Carolina, 29303, United States

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri, 63303, United States

  • Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden

    Esbjerg, 6700, Denmark

  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

    Senhora Da Hora, Matosinhos, Matosinhos, 4464-513, Portugal

  • UZ Leuven - Endocrinology

    Leuven, 3000, Belgium

  • UZA - UZ Antwerpen - Department of Endocrinology

    Edegem, 2650, Belgium

  • Unidade Local de Saude de Sao Joao E.P.E

    Porto, 4200-319, Portugal

  • University Hospital Coventry - WISDEM Centre

    Coventry, CV2 2DX, United Kingdom

  • Valley Clinical Trials

    Covina, California, 91723, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Yale University School Of Medicine

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.